Nurix Historical Cash Flow
| NRIX Stock | USD 12.99 0.88 6.34% |
Analysis of Nurix Therapeutics cash flow over time is an excellent tool to project Nurix Therapeutics future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Begin Period Cash Flow of 62.7 M or Total Cashflows From Investing Activities of 25.7 M as it is a great indicator of Nurix Therapeutics ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining Nurix Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Nurix Therapeutics is a good buy for the upcoming year.
Nurix |
About Nurix Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in Nurix balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Nurix's non-liquid assets can be easily converted into cash.
Nurix Therapeutics Cash Flow Chart
Add Fundamental
Free Cash Flow
The amount of cash a company generates after accounting for cash outflows to support operations and maintain its capital assets.Begin Period Cash Flow
The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.Depreciation
Depreciation indicates how much of Nurix Therapeutics value has been used up. For tax purposes Nurix Therapeutics can deduct the cost of the tangible assets it purchases as business expenses. However, Nurix Therapeutics must depreciate these assets in accordance with IRS rules about how and when the deduction may be taken, and how long it will last. The systematic allocation of the cost of a tangible asset over its useful life.Capital Expenditures
Capital Expenditures are funds used by Nurix Therapeutics to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of Nurix Therapeutics operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.Most accounts from Nurix Therapeutics' cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Nurix Therapeutics current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Nurix Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. For more information on how to buy Nurix Stock please use our How to Invest in Nurix Therapeutics guide.At this time, Nurix Therapeutics' Sale Purchase Of Stock is fairly stable compared to the past year. Change In Cash is likely to rise to about 66.9 M in 2025, despite the fact that Investments are likely to grow to (220.3 M).
Nurix Therapeutics cash flow statement Correlations
Click cells to compare fundamentals
Nurix Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Nurix Therapeutics cash flow statement Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Sale Purchase Of Stock | (16K) | (7K) | (1K) | 117.2M | 134.8M | 141.5M | |
| Investments | (102.6M) | 39.4M | 68.3M | (257.7M) | (231.9M) | (220.3M) | |
| Change In Cash | (38.7M) | (15.4M) | (9.8M) | 55.4M | 63.7M | 66.9M | |
| Stock Based Compensation | 15.8M | 28.1M | 33.7M | 33.9M | 39.0M | 41.0M | |
| Free Cash Flow | (90.0M) | (172.1M) | (89.8M) | (181.9M) | (163.7M) | (155.5M) | |
| Change In Working Capital | 9.1M | (19.0M) | 20.1M | (18.4M) | (16.6M) | (15.7M) | |
| Begin Period Cash Flow | 119.5M | 80.8M | 65.4M | 55.5M | 63.9M | 62.7M | |
| Total Cashflows From Investing Activities | 8.5M | (254.4M) | (108.3M) | 27.2M | 24.5M | 25.7M | |
| Other Cashflows From Financing Activities | 3.7M | 97.8M | 3.2M | 7.2M | 8.2M | 7.8M | |
| Depreciation | 6.1M | 10.8M | 13.7M | (2.0M) | (2.3M) | (2.2M) | |
| Other Non Cash Items | 1.8M | 636K | (4.9M) | (11.0M) | (9.9M) | (9.4M) | |
| Capital Expenditures | 5.7M | 12.2M | 8.4M | 9.3M | 10.7M | 6.8M | |
| Total Cash From Operating Activities | (84.4M) | (159.8M) | (81.4M) | (172.6M) | (155.3M) | (147.6M) | |
| Change To Operating Activities | 2.4M | (1.7M) | (4.4M) | 1.5M | 1.4M | 1.4M | |
| Net Income | (117.2M) | (180.4M) | (143.9M) | (193.6M) | (174.2M) | (165.5M) | |
| Total Cash From Financing Activities | 153.9M | 117.2M | 3.2M | 485.7M | 558.5M | 586.4M | |
| End Period Cash Flow | 80.8M | 65.4M | 55.5M | 110.9M | 127.5M | 77.5M | |
| Other Cashflows From Investing Activities | 10.1M | (249.9M) | (102.6M) | 39.4M | 35.5M | 37.3M | |
| Change To Netincome | 401K | 4.6M | 17.6M | 28.3M | 32.6M | 34.2M | |
| Change To Liabilities | 17.2M | 49.4M | 8.3M | 7.6M | 8.7M | 9.8M | |
| Issuance Of Capital Stock | 150.2M | 19.4M | 0.0 | 478.5M | 550.3M | 577.8M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Additional Tools for Nurix Stock Analysis
When running Nurix Therapeutics' price analysis, check to measure Nurix Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nurix Therapeutics is operating at the current time. Most of Nurix Therapeutics' value examination focuses on studying past and present price action to predict the probability of Nurix Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nurix Therapeutics' price. Additionally, you may evaluate how the addition of Nurix Therapeutics to your portfolios can decrease your overall portfolio volatility.